Analysis of Brain Diffusion Tensor Image in Stroke Patients
NCT06047223, Unknown, Bundang CHA Hospital
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Analysis of Brain Diffusion Tensor Image in Stroke Patients | ClinicalTrials.gov |
| NCT number | NCT06047223 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Enrollment | 80 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Bundang CHA Hospital | ClinicalTrials.gov |
| Conditions | Stroke | ClinicalTrials.gov |
| Interventions | Magnetic resonanace imaging | ClinicalTrials.gov |
| First posted | 2023-09-21 | ClinicalTrials.gov |
| Last updated | 2023-11-18 | ClinicalTrials.gov |
Registered outcomes 19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Measurement of magnetic resonanace imaging (MRI) | Through study completion, an average of 1 day | MRI scan is a process of measuring changes of diffusion tensor tractography | ClinicalTrials.gov |
| Secondary | Measurement of Korean version of coma recovery scale-revised (K-CRSR) | Through study completion, an average of 1 day | K-CRSR is Korean version of standardized neurobehavioral assessment measure designed for use in patients with disorders of consciousness. he scale is intended to be used to establish diagnosis, monitor behavioral recovery, predict outcome, and assess treatment effectiveness. | ClinicalTrials.gov |
| Secondary | Measurement of Korean version of Montreal Cognitive Assessment (K-MoCA) | Through study completion, an average of 1 day | K-MoCA is a measurement to evaluate the memory loss or other symptoms of cognitive decline. It contains 30 questions and taskes around to 12 minutes to complete. Scores range from 0 to 30. A score of 26 and higher is considered normal. | ClinicalTrials.gov |
| Secondary | Measurement of clinical dementia rate (CDR) | Through study completion, an average of 1 day | CDR is a rating scale for staging patients diagnosed with dementia. The CDR evaluates cognitive, behavioral and functional aspects of Alzheimer disease and other dementias. It is calculated on the basis of testing six different cognitive and behavioral domains such as memory, orientation, judgment and problem sloving, community affairs, home and hobbies performance, and personal care. The CDR is based on a scale of 0-3: no dementia (CDR = 0), questionable dementia (CDR = 0.5), MCI (CDR = 1), moderate cognitive impairment (CDR = 2) and severe cognitive impairment (CDR = 3) | ClinicalTrials.gov |
| Secondary | Measurement of Korean version of oxford cognitive screen (OCS-K) | visit 1 | OCS is an assessment of major cognitive domains of memory, language, number, praxis, executive functions and attention. | ClinicalTrials.gov |
| Secondary | Measurement of digit span test. | Through study completion, an average of 1 day | Digit span test is a measurment to assess the storage capacity of a person's working memory. A testperson is visually or auditorily to a sequence of digits on after another. Right afterwards, the test subject has to recall the correct digits in the same order. | ClinicalTrials.gov |
| Secondary | Measurement of digit span test. | Through study completion, an average of 1 day | inhibit cognitie interference. The stroop test consists of colors that are writen in words but in the wrong color ink, The test-taker has to be able to state the color that the word is written in and be able to ignore whatever the actual word is. | ClinicalTrials.gov |
| Secondary | Measurement of Korean version of western aphasia battery (K-WAB) | Through study completion, an average of 1 day | K-WAB is designed as an assessment tool to examine linguistic skills (information content, fluency, auditory comprehension, repetition, naming and word finding, reading, and writing) and main nonlinguistic skills (drawing, block design, calculation, and praxis) of adults with aphasia. | ClinicalTrials.gov |
| Secondary | Measurement of motricity index (MI) | Through study completion, an average of 1 day | MI is a process of the evaluating the function and strength of upper, lower extremities and trunk in score. | ClinicalTrials.gov |
| Secondary | Measurement of berg balance scale (BBS) | Through study completion, an average of 1 day | BBS is a measurement of balancing function. A five-point ordinal scale, ranging from 0-4. "0" indicates the lowest level of function and "4" the highest level of function. Total score = 56 | ClinicalTrials.gov |
| Secondary | Measurement of functional ambulatory category (FAC) | Through study completion, an average of 1 day | FAC is a measurement of a functional walking test that evaluates ambulation ability. This 6-point scale assesses ambulation status by determining how much human support the patient requires when walking, regardless of whether or not they use personal assistive device. | ClinicalTrials.gov |
| Secondary | Measurement of time up and go (TUG) | Through study completion, an average of 1 day | TUG is a measurement of a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down. 11-20 seconds are within normal limits for frail elderly and disables patients, and greater than 20 seconds means the person needs assistance outside and indicates further examintaiton and intervention. A score of 30 seconds or more suggests that the person may be prone to falls. | ClinicalTrials.gov |
| Secondary | Measurement of Fugl-Meyer assessment (FMA) | Through study completion, an average of 1 day | FMA is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sesation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research determine disease severity, describe motor recovery, and to plan and assess treatment. | ClinicalTrials.gov |
| Secondary | Measurement of action research arm test (ARAT) | Through study completion, an average of 1 day | ARAT is a 19 item observational measurement to assess upper extremity performance (coordination, dexterity and functioning). Items comprising ARAT are categorized into four subscales (grasp, grip, pinch and gross movement). Task performance is rated on a 4-point scale, ranging from 0 (no movement) to 3 (movement performend normally) | ClinicalTrials.gov |
| Secondary | Measurement of Korean version of modified barthel index (K-MBI) | Through study completion, an average of 1 day | MBI is a measurement of degree of independence of a patient from any assistance. It covers 10 domains of daily activities: bowel and bladder control, grooming, toilet use, feeding, trasnfers, walking, dressing, climbing stairs and bathing | ClinicalTrials.gov |
| Secondary | Measurement of motion analysis | Through study completion, an average of 1 day | Motion analysis is a process of measuring and evaluating gait function in kinetic parameters of range of motion in angle of each joint by degree throguh Qualisys motion analysis system | ClinicalTrials.gov |
| Secondary | Measurement of motion analysis | Through study completion, an average of 1 day | Motion analysis is a process of measuring and evaluating gait function and kinematic parameters including moment (Nm/kg) of each joint throguh Qualisys motion analysis system | ClinicalTrials.gov |
| Secondary | Measurement of motion analysis | Through study completion, an average of 1 day | Motion analysis is a process of measuring and evaluating gait function and kinematic parameters including power (Nm/s\*kg) of each joint throguh Qualisys motion analysis system | ClinicalTrials.gov |
| Secondary | Measurement of motion analysis | Through study completion, an average of 1 day | Motion analysis is a process of measuring and evaluating gait function and kinematic parameters including ground reaction force (N/kg) of each joint throguh Qualisys motion analysis system | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)